DanioLabs and Senexis enter AD drug R&D accord

DanioLabs, a neurology and ophthalmology drug reprofiling company, has signed a strategic collaboration with fellow UK-based Senexis, a privately-held drug development company, focused on discovering new treatments for aging-related diseases.

DanioLabs has pioneered development of medium/high throughput, high content in vivo assays utilizing its cutting edge zebrafish technology. Known drugs and pharmacological probes are screened with a view to minimizing the risk of drug development. It has two programs with positive clinical data and a strong preclinical pipeline. DanioLabs has a major neurodegeneration program covering Parkinson's, Alzheimer's and Huntington's diseases, as well as multiple sclerosis. It is currently screening for small molecules which rescue the underlying pathologies of these disease states, as well as ameliorating the cognitive impairment associated with various forms of dementias.

Senexis is developing New Chemical Entities as inhibitors of amyloid-related toxicity and inflammation in Alzheimer's disease. The firms expect the combination of the two complementary approaches will offer a significant opportunity to develop novel molecules with the potential of becoming disease-modifying therapies for AD.